[go: up one dir, main page]

MX2009006170A - Compuestos y composiciones como inhibidores de cinasa. - Google Patents

Compuestos y composiciones como inhibidores de cinasa.

Info

Publication number
MX2009006170A
MX2009006170A MX2009006170A MX2009006170A MX2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A MX 2009006170 A MX2009006170 A MX 2009006170A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
kinase inhibitors
trkc
trkb
Prior art date
Application number
MX2009006170A
Other languages
English (en)
Inventor
Yi Fan
Yuan Mi
Ha-Soon Choi
Pamela Albaugh
Shenlin Huang
Zuosheng Liu
Original Assignee
Irmc Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irmc Llc filed Critical Irmc Llc
Publication of MX2009006170A publication Critical patent/MX2009006170A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona una clase novedosa de compuestos, composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos para tratar o prevenir enfermedades o los trastornos asociados con una actividad de cinasa anormal o mal regulada, en particular de TrkA, TrkB, TrkC, PDGFR y c-kit.
MX2009006170A 2006-12-11 2007-12-11 Compuestos y composiciones como inhibidores de cinasa. MX2009006170A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86954806P 2006-12-11 2006-12-11
PCT/US2007/025447 WO2008073480A1 (en) 2006-12-11 2007-12-11 Compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009006170A true MX2009006170A (es) 2009-06-19

Family

ID=39132188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006170A MX2009006170A (es) 2006-12-11 2007-12-11 Compuestos y composiciones como inhibidores de cinasa.

Country Status (11)

Country Link
US (1) US20100168182A1 (es)
EP (1) EP2102190A1 (es)
JP (1) JP2010512405A (es)
KR (1) KR20090092317A (es)
CN (1) CN101541788A (es)
AU (1) AU2007333536A1 (es)
BR (1) BRPI0720059A2 (es)
CA (1) CA2672101A1 (es)
EA (1) EA200900783A1 (es)
MX (1) MX2009006170A (es)
WO (1) WO2008073480A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
IN2014MN02105A (es) 2012-04-20 2015-09-11 Annji Pharm Co Ltd
CN102718659B (zh) * 2012-06-27 2014-12-17 东南大学 一种4-溴-2-硝基苯乙酸的合成方法
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US10085979B2 (en) 2014-12-02 2018-10-02 Ignyta, Inc. Combinations for the treatment of neuroblastoma
CN105001167B (zh) * 2015-07-16 2018-01-05 西安交通大学 1‑取代苯基‑3‑（4‑取代苯基氨基‑6‑喹唑啉基）脲类化合物及制备方法和用途
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN105669521B (zh) * 2016-01-14 2019-01-15 成都知普莱生物医药科技有限公司 抗肿瘤化合物及其制备方法和应用
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045731A1 (es) * 2003-08-06 2005-11-09 Vertex Pharma Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas
RU2401265C2 (ru) * 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
EP2102190A1 (en) 2009-09-23
KR20090092317A (ko) 2009-08-31
EA200900783A1 (ru) 2009-12-30
BRPI0720059A2 (pt) 2013-12-17
CN101541788A (zh) 2009-09-23
JP2010512405A (ja) 2010-04-22
WO2008073480A1 (en) 2008-06-19
US20100168182A1 (en) 2010-07-01
CA2672101A1 (en) 2008-06-19
AU2007333536A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
TW200942537A (en) Compounds and compositions as kinase inhibitors
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
ATE544761T1 (de) Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2010003117A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
MX2008002166A (es) Compuestos y composiciones como mimeticos de trombopoietina (tpo).

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal